title: [Advance of molecular subtyping and precise treatment for gliomas].
abstract: With the advance of genomics research, there have been a new breakthrough in the molecular classification of gliomas. Glioblastoma (WHO grade Ⅳ) could be subtyped to proneural, neural, classical, and mesochymal according to the mRNA expression. Lower grade gliomas (WHO grade Ⅱ and Ⅲ) could be divided into 5 types using 1p/19q co-deletion, isocitrate dehydrogenase(IDH) mutation, and TERTp (promotor region) mutation. In 2016, a new classification of tumors of the central nervous system was proposed, and some new markers such as IDH1 mutation were introduced into the diagnosis of gliomas. Genotype and phenotype were integrated to diagnose gliomas. In the meantime, precision treatment for gliomas has also been vigorously developed. This article reviewed recent studies on the molecular diagnosis, precise chemotherapy, targeted therapy, and immunotherapy for gliomas to provide new ideas and strategies for precise diagnosis and treatment of gliomas.
authors.affiliation: Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
authors.forename: W
authors.initials: W
authors.lastname: Hua
authors.forename: Y
authors.initials: Y
authors.lastname: Mao
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1; D023281:Genomics; D005909:Glioblastoma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D005910:Glioma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D006801:Humans; D007521:Isocitrate Dehydrogenase; D009154:Mutation; D057285:Precision Medicine; D011379:Prognosis
chemical_list: D007521:Isocitrate Dehydrogenase